These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17987008)

  • 21. Drug-review deadlines and safety problems.
    Nardinelli C; Lanthier M; Temple R
    N Engl J Med; 2008 Jul; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA continues to monitor dental amalgam use.
    Dent Today; 2002 Apr; 21(4):38, 40-1. PubMed ID: 11957232
    [No Abstract]   [Full Text] [Related]  

  • 24. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 26. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 28. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 29. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    Schiller LR; Johnson DA
    Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premier databases to support FDA surveillance related to drug safety.
    Health Care Strateg Manage; 2001 Nov; 19(11):10. PubMed ID: 11729600
    [No Abstract]   [Full Text] [Related]  

  • 31. Failure to report harms and adverse events in clinical trials: why does the problem continue?
    Miller DR
    Can J Anaesth; 2012 Nov; 59(11):1007-12. PubMed ID: 22936571
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA proposes tightening post-market oversight of medical devices.
    Roehr B
    BMJ; 2012 Sep; 345():e6140. PubMed ID: 22968864
    [No Abstract]   [Full Text] [Related]  

  • 33. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New FDA regulation to improve safety reporting in clinical trials.
    Sherman RB; Woodcock J; Norden J; Grandinetti C; Temple RJ
    N Engl J Med; 2011 Jul; 365(1):3-5. PubMed ID: 21651388
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA warns of stroke risk associated with phenylpropanolamine; cold remedies and drugs removed from store shelves.
    SoRelle R
    Circulation; 2000 Nov; 102(21):E9041-3. PubMed ID: 11185472
    [No Abstract]   [Full Text] [Related]  

  • 36. Fort Dodge recalls ProHeart 6, citing FDA safety concerns. Advisory committee to review FDA findings.
    Kuehn BM
    J Am Vet Med Assoc; 2004 Oct; 225(8):1157-8. PubMed ID: 15521431
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of vaginal mesh in the face of the recent FDA warnings and litigation.
    Steinberg AC
    Am J Obstet Gynecol; 2011 Jun; 204(6):e10; author reply e10-1. PubMed ID: 21292232
    [No Abstract]   [Full Text] [Related]  

  • 38. The FDA and new safety warnings.
    Moore TJ; Singh S; Furberg CD
    Arch Intern Med; 2012 Jan; 172(1):78-80. PubMed ID: 22232155
    [No Abstract]   [Full Text] [Related]  

  • 39. Roadmap for revitalization?
    Nat Biotechnol; 2007 Oct; 25(10):1061. PubMed ID: 17921973
    [No Abstract]   [Full Text] [Related]  

  • 40. The FDA and safety--beyond the heparin crisis.
    Laurencin CT; Nair L
    Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.